ICICI Direct's research report on Sanofi India
Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy. Around 70% of sales stem from top seven brands. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India • Sanofi enjoys strong brand recall in anti-diabetic therapy in India.
Outlook
Maintain HOLD as we wait for visible growth triggers in power brands portfolio especially in the anti-diabetic and cardiovascular therapies. Valued at Rs 6385 i.e. 25x P/E on FY24E EPS on Rs 255.5.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
